A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds

Cumashi, Albana; Ушакова, Н. А.; Preobrazhenskaya, M. E.; D’Incecco, Armida; Piccoli, Antônio; Totani, Licia; Tinari, Nicola; Morozevich, G. E.; Berman, A. E.; Bilan, Maria I.; Усов, А. И.; Ustyuzhanina, Nadezhda E.; Грачев, А. А.; Sanderson, Craig J.; Kelly, Maeve; Rabinovich, Gabriel A.; Iacobelli, Stéfano; Nifantiev, Nikolay E.

doi:10.1093/glycob/cwm014

Cited by 871 publications

(657 citation statements)

References 49 publications

Supporting

Mentioning

610

Contrasting

Unclassified

Order By: Relevance

“…Fucoidans effectively inhibit leukocyte recruitment to inflamed peritoneum in rats (Preobrazhenskaya et al, 1997;Cumashi et al, 2007). In vitro evaluation showed inhibition of P-selectin-mediated neutrophil adhesion to platelets under flow conditions.…”

Section: P-selectin Inhibitionmentioning

confidence: 97%

Novel uses for anti‐platelet agents as anti‐inflammatory drugs

Pitchford

2007

British J Pharmacology

View full text Add to dashboard Cite

An alteration in the character and function of platelets is manifested in patients with inflammatory diseases, and these alterations have been dissociated from the well‐characterized involvement of platelets in thrombosis and haemostasis. Recent evidence reveals platelet activation is sometimes critical in the development of inflammation. The mechanisms by which platelets participate in inflammation are diverse, and offer numerous opportunities for future drug intervention. There is now acceptance that platelets act as innate inflammatory cells in immune responses, with roles as sentinel cells undergoing surveillance, responding to microbial invasion, orchestrating leukocyte recruitment, and migrating through tissue, causing damage and influencing repair processes in chronic disease. Some of these processes are targeted by drugs that are being developed to target platelet participation in atherosclerosis. The actions of platelets therefore influence the pathogenesis of diverse inflammatory diseases in various body compartments, encompassing parasitic and bacterial infection, allergic inflammation (especially asthma and rhinitis), and non‐atopic inflammatory conditions, for example, chronic obstructive pulmonary disease (COPD), rheumatoid arthritis (RA), inflammatory bowel disease (IBD) and atherosclerosis. This review will first discuss the evidence for platelet activation in these various inflammatory diseases, and secondly discuss the mechanisms by which this pathogenesis occurs and the various anti‐platelet agents which have been developed to combat platelet activation in atherosclerosis and their potential future use for the treatment of other inflammatory diseases.British Journal of Pharmacology (2007) 152, 987–1002; doi:10.1038/sj.bjp.0707364; published online 2 July 2007

show abstract

Section: P-selectin Inhibitionmentioning

confidence: 97%

Novel uses for anti‐platelet agents as anti‐inflammatory drugs

Pitchford

2007

British J Pharmacology

View full text Add to dashboard Cite

show abstract

“…This botanical polymer shares chemical analogies with heparin, a sulfated polysaccharide of animal origin, but exhibits lower anticoagulant activity. 14 Algal fucoidans have been characterized as having a wide variety of biological activities in vivo and in vitro, including anti-inflammatory, antioxidative, and antiaggregative 14,15 properties that all seem to be beneficial for alleviation of diabetic injury. In previous studies, we have successfully prepared and characterized a low-molecular-weight fucoidan (LMWF, 7000 Da) from L aminaria japonica that shares similar biological activities with other fucoidans.…”

mentioning

confidence: 99%

Low-molecular-weight fucoidan protects endothelial function and ameliorates basal hypertension in diabetic Goto-Kakizaki rats

Cui

Zheng

Zhang

et al. 2014

Laboratory Investigation

View full text Add to dashboard Cite

Endothelial dysfunction, characterized by impairment of endothelial nitric oxide synthase (eNOS) and nitric oxide (NO) bioavailability, has been implicated in diabetic cardiovascular pathogenesis. In this study, low-molecular-weight fucoidan (LMWF), which has multiple biological activities including anti-inflammatory and anti-oxidative properties, was investigated for its protective effect against endothelial dysfunction in Goto-Kakizaki type 2 diabetic rats. LMWF (50, 100, or 200 mg/kg/day) or probucol (100 mg/kg/day) were given to diabetic rats for 12 weeks. Basal blood pressure, acetylcholine-or flow-mediated relaxation of mesenteric and paw arteries, endothelium-dependent dilation of aorta, eNOS phosphorylation, and NO production were measured using laser Doppler flowmetry, force myograph, hematoxylin and eosin staining, western blot analysis, and an NO assay. We found that LMWF robustly ameliorated the basal hypertension and impairment of endothelium-dependent relaxation in the aorta, as well as mesenteric and paw arteries in diabetic rats. In addition, the reduction in eNOS phosphorylation at Ser1177, eNOS expression, and NO production because of diabetes were partially reversed by LMWF treatment. However, probucol, a lipid-modifying drug with antioxidant properties, displayed only mild effects. Moreover, LMWF induced, in a dose-dependent manner, endotheliumdependent vasodilation and eNOS phosphorylation at Ser1177 in normal aorta, and also promoted Ser1177 phosphorylation and NO synthesis in primary cultured vasoendothelial cells. Thus, these data demonstrate for the first time that fucoidan protects vasoendothelial function and reduces basal blood pressure in type 2 diabetes rats via, at least in part, preservation of eNOS function. Fucoidan is therefore a potential candidate drug for protection of endothelium in diabetic cardiovascular complications. KEYWORDS: diabetes; endothelium-dependent vasodilation; endothelial nitric oxide synthase; low-molecular-weight fucoidan; nitric oxide Diabetic patients are at high risk of endothelial dysfunction and vascular lesions, because of multiple harmful stimuli, such as hyperglycemia, hyperlipidemia, and oxidative stress. These patients are susceptible to atherosclerosis, hypertension, and peripheral vascular disease. 1,2 It is well established that endothelium-derived nitric oxide (NO) maintains vascular homeostasis and health through vasodilation and protection of vasculature from various damaging agents. [3][4][5] Loss of NO induces increased activity of proinflammatory transcription factors, such as nuclear factor kappa B, resulting in expression of leukocyte adhesion molecules and production of chemokines and cytokines, which further promote endothelial inflammation and atherosclerosis. 5,6 Therefore, the endothelial dysfunction caused by imbalance of NO bioavailability in early-stage diabetes has been implicated as a sign or a predictor of a future cardiovascular event. [6][7][8] Mechanistically, a disturbance in endothelial NO synthase (eNOS) activity, refe...

show abstract

“…Brown algae contains sulfated fucans that exhibit biomedical functions in inflammation, coagulation, angiogenesis, and cell adhesion (Cumashi et al, 2007). Green and red algae also contain sulfated galactans that involve many pathophysiological systems.…”

Section: Discussionmentioning

confidence: 99%

Detection of a Non-animal Source of Glycosaminoglycans from Edible Mushrooms in Northern Thailand

Choocheep¹,

Nathip²

2018

CMUJNS

View full text Add to dashboard Cite

Several kinds of cultivated or local edible mushrooms exist in northern Thailand. While their nutritional features have been extensively analyzed, the presence of phytochemicals and glycosaminoglycans has yet to be investigated. Thus, in this study, we examined the presence of phytochemicals and glycosaminoglycans from 10 cultivated or local mushrooms: milk white russula, hygroscopic earthstar, log white fungi, log black fungi, shitake mushroom, rosy russula, sajor-caju mushroom, Jew's ear, bolete, and straw mushroom. Phytochemical analysis revealed the presence of carbohydrates, amino acids, and flavonoids in the extracts from most of the mushrooms. We detected glycosaminoglycans in all of the extracts using dimethylmethylene blue (DMMB) dye-binding assay and UVVis spectrophotometry. Hygroscopic earthstar contained the most glycosaminoglycans and sajor-caju mushroom the least. However, we were unable to distinguish the types of glycosaminoglycans, which should be considered for future study. In summary, the phytochemicals found here are crucial non-animal dietary sources of carbohydrates, amino acids, and antioxidants. In addition, the glycosaminoglycans detected in the mushroom extracts in this study potentially offer a non-animal source of glycosaminoglycans that may have clinical applications, apart from their nutritive value.

show abstract

A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds

Cited by 871 publications

References 49 publications

Novel uses for anti‐platelet agents as anti‐inflammatory drugs

Novel uses for anti‐platelet agents as anti‐inflammatory drugs

Low-molecular-weight fucoidan protects endothelial function and ameliorates basal hypertension in diabetic Goto-Kakizaki rats

Detection of a Non-animal Source of Glycosaminoglycans from Edible Mushrooms in Northern Thailand

Contact Info

Product

Resources

About